In the most recent reporting.

In the most recent reporting, the participants were romantic partners were asked to share their experiences and their partners while expressing emotions to describe their relationship. Interactions of the couples were also observed and evaluate evaluate the expression of emotions and their interpersonal dynamics.

Read the full text of articles and show the questionnaire. – The Journal of Bone and Joint Surgery – British Volume is a leading orthopedic journal with an impact factor of 1.868 – JBJS-Br published twelve issues per year of high-quality, peer-reviewed research, supervised by an international editorial by Editor James Scott led – the Journal was first published in 1948 by British Editorial Society of Bone and Joint Surgery, a registered charity , with the objective of development and improvement of education in orthopedic surgery and allied branches of surgery and the dissemination of knowledge about new and improved methods of teaching and practicing orthopedic surgery in all its branches..Long time SPRYCEL to adult patients with newly diagnosed CML.

Bristol-Myers Squibb reported today that SPRYCEL has received 100 mg once daily market approval of the European Commission to the treatment of adults patients newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase . Sprycel be the first new treatment EU approval to the superior efficacy compared to Glivec this indication since 2001. Which authorization is limited to the results of the DASISION open-label, phase 3 study, to late-breaking background a 46th Been submitted to annual American Journal of Clinical Oncology, at the Best Abstracts section of the Presidential Symposium the the fifteenth Congress of EHA and published in The New England Journal of Medicine in June 2013.[1] The study is not yet complete and For more data are needed in order determine long – term Results The.

Dasatinib is displays excellent response rates compared with imatinib[1].

In DASISION study demonstrated dasatinib is superior activity to higher and faster molecular mass and confirms cytogenetical compared to Glivec to 12 months in newly diagnosed CP – CML patients Seventy.-seven %[95 percent CI: 71 – 82] of dasatinib-treated patients vs. 66 percent[95 percent CI: 60 – 72] imatinib responders achieved the primary endpoint the certified CCyR at 12 months was 6.3 months. One hundred thirty-five dasatinib responders and 9.2 months in 88 imatinib respond MMR at anytime dasatinib patient was greater vs. Imatinib .